Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

被引：146

作者：

Cragg, Mark S. ^{[1
,3
]}

Harris, Claire ^{[3
]}

Strasser, Andreas ^{[1
]}

Scott, Clare L. ^{[1
,2
]}

机构：

[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia

[2] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic 3050, Australia

[3] Univ Southampton, Canc Sci Div, Sch Med, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England

来源：

NATURE REVIEWS CANCER | 2009年 / 9卷 / 05期

关键词：

BCL-2 FAMILY PROTEINS; SMALL-MOLECULE INHIBITOR; B-CELL LYMPHOMA; LUNG-CANCER; EGFR MUTATIONS; ABL KINASE; IN-VITRO; ABT-737; RESISTANCE; APOPTOSIS;

D O I：

10.1038/nrc2615

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapeutic targeting Of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, Cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, Such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.

引用

收藏

页码：321 / 326

页数：6

相关论文

共 57 条

[21] Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia [J].

Kuroda, J. ;

Kimura, S. ;

Strasser, A. ;

Andreeff, M. ;

O'Reilly, L. A. ;

Ashihara, E. ;

Kamitsuji, Y. ;

Yokota, A. ;

Kawata, E. ;

Takeuchi, M. ;

Tanaka, R. ;

Tabe, Y. ;

Taniwaki, M. ;

Maekawa, T. .

CELL DEATH AND DIFFERENTIATION, 2007, 14 (09) :1667-1677

[22]

Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103

[23] Involvement of BH3-only proteins in hematologic malignancies [J].

Kuroda, Junya ;

Taniwaki, Masafumi .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) :89-101

[24] Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737 [J].

Kutuk, Ozgur ;

Letai, Anthony .

CANCER RESEARCH, 2008, 68 (19) :7985-7994

[25] BCL-2 family antagonists for cancer therapy [J].

Lessene, Guillaume ;

Czabotar, Peter E. ;

Colman, Peter M. .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) :989-1000

[26] Diagnosing and exploiting cancer's addiction to blocks in apoptosis [J].

Letai, Anthony G. .

NATURE REVIEWS CANCER, 2008, 8 (02) :121-132

[27] 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 [J].

Lin, X. ;

Morgan-Lappe, S. ;

Huang, X. ;

Li, L. ;

Zakula, D. M. ;

Vernetti, L. A. ;

Fesik, S. W. ;

Shen, Y. .

ONCOGENE, 2007, 26 (27) :3972-3979

[28] Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program [J].

Lock, Richard ;

Carol, Hernan ;

Houghton, Peter J. ;

Morton, Christopher L. ;

Kolb, E. Anders ;

Gorlick, Richard ;

Reynolds, C. Patrick ;

Maris, John M. ;

Keir, Stephen T. ;

Wu, Jianrong ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (06) :1181-1189

[29] In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas [J].

Mason, Kylie D. ;

Vandenberg, Cassandra J. ;

Scott, Clare L. ;

Wei, Andrew H. ;

Cory, Suzanne ;

Huang, David C. S. ;

Roberts, Andrew W. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (46) :17961-17966

[30] BH3 Mimetic ABT-737 and a Proteasome Inhibitor Synergistically Kill Melanomas through Noxa-Dependent Apoptosis [J].

Miller, Leslie A. ;

Goldstein, Nathaniel B. ;

Johannes, Widya U. ;

Walton, Christine H. ;

Fujita, Mayumi ;

Norris, David A. ;

Shellman, Yiqun G. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (04) :964-971

← 1 2 3 4 5 6 →